Tiansheng Pharmaceutical Group (002872.SZ): Sodium bicarbonate injection passes the evaluation of generic drug consistency.

Tiansheng Pharmaceutical Group (002872.SZ) announced that its wholly-owned subsidiary Hubei Tiansheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Hubei Tiansheng") recently received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration. The Hubei Tiansheng product "Sodium Bicarbonate Injection" has passed the generic drug quality and efficacy consistency evaluation. Clinically, Sodium Bicarbonate Injection is mainly used for: (1) treating metabolic acidosis; (2) alkalinizing urine; (3) intravenous infusion for nonspecific treatment of certain drug poisonings. Sodium Bicarbonate Injection is listed as a variety in the "National Essential Medicines List (2018)" and a Class A variety in the "National Basic Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Drug List (2024)". The successful consistency evaluation of the Hubei Tiansheng product "Sodium Bicarbonate Injection" will help enhance the market competitiveness of the drug, and also accumulate experience for the company to conduct consistency evaluation work for other generic drugs in the future.